Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Telix Pharma
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
2023-05-08 05:00
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
2023-05-08 05:00
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
2023-05-02 05:00
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
2023-05-01 08:58
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
2023-04-27 06:50
Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter
2023-04-17 18:15
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
2023-04-17 06:38
Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate
2023-04-11 05:00
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
2023-03-16 20:28
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
2023-03-16 08:28
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
2023-03-14 05:11
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
2023-03-09 04:51
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
2023-02-27 14:37
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
2023-02-20 07:10
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
2023-02-15 04:51
Telix Reports Fourth Quarter 2022 Financial Results
2023-01-18 08:50
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
2023-01-09 06:37
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
2022-12-22 06:04
Telix Announces Executive Leadership Appointments
2022-12-05 06:39
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
2022-11-22 20:00
1
2
3
4
5
6